ArticleJournal of neuro-oncology2026
Care pathways for asymptomatic brain metastases: comparison of healthcare utilization, costs, and outcomes in outpatient versus acute settings.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeIncidentally found brain metastases often lead to emergency room referrals even in asymptomatic patients-a pathway of care that could be unnecessary. We sought to compare time and financial toxicity, and treatment outcomes between a multidisciplinary outpatient (MP) and acute care pathways (AP).
methodsPatients referred for de novo asymptomatic brain metastases at an NCI-designated Cancer Center with a Multidisciplinary Brain Metastasis Program were identified via retrospective review. Scans, encounters, time to local interventions, and survival data were collected and compared.
resultsSeventy-eight patients were identified, 47 referred to MP and 31 AP. Both groups had similar disease-specific prognostic scores and received similar treatments. Patients managed via AP had larger dominant lesions (2.9 cm vs. 2.0 cm, p < 0.002) and shorter time to therapy (13.7 days vs. 9.2 days; p = 0.047). AP patients also had more medical-encounter (7.1 vs. 2.5; p < 0.001) and admitted days (5.9 vs. 1.1; p < 0.001), with increased median gross charge amount ($185,961 vs. $126,831; p = 0.003) despite similar 6-month survival (83% MP vs. 81% AP, p > 0.999) and local tumor control (95% MP vs. 96% AP, p = 0.849).
conclusionPatients with asymptomatic brain metastases managed through an outpatient pathway attained similar disease outcomes with lower time and financial toxicity compared to patients managed through inpatient pathways. Characteristics of such patients that qualify them for outpatient pathway should be confirmed prospectively.
Indexed as
Identifiers
42151637What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.